BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO
This review included patients receiving phlebotomy alone (n=103) and each of the following cytoreductive therapies with or without concomitant phlebotomy: hydroxyurea (n=165), ruxolitinib (n=115), peginterferon alfa-2a (n=44) and ropeginterferon alfa-2b (n=45).
- This review included patients receiving phlebotomy alone (n=103) and each of the following cytoreductive therapies with or without concomitant phlebotomy: hydroxyurea (n=165), ruxolitinib (n=115), peginterferon alfa-2a (n=44) and ropeginterferon alfa-2b (n=45).
- They observed a reduction for hydroxyurea from 7 to 4 patients (43%); in ruxolitinib from11 to 6 patients (45%), and in peginterferon alfa-2a from12 to 8 patients (33%).
- In this review, 63% of patients were identified as high risk (>60 y/o with history of thrombosis).
- “Polycythemia vera is a chronic blood disorder which is now recognized as a type of cancer.